Literature DB >> 35094358

Selection of Cancer Stem Cell-Targeting Agents Using Bacteriophage Display.

Austin R Prater1, Susan L Deutscher2.   

Abstract

There is a growing need to develop tumor targeting agents for aggressive cancers. Aggressive cancers frequently relapse and are resistant to various therapies. Cancer stem cells (CSCs) are believed to be the cause of relapse and the aggressive nature of many cancers. Targeting CSCs could lead to novel diagnostic and treatment options. Bacteriophage (phage) display is a powerful tool developed by George Smith in 1985 to aid in the discovery of CSC targeting agents. Phage display selections are typically performed in vitro against an immobilized target. There are inherent disadvantages with this technique that can be circumvented by performing phage display selections in vivo. However, in vivo phage display selections present new challenges. A combination of both in vitro and in vivo selections, however, can take advantage of both selection methods. In this chapter, we discuss in detail how to isolate a CSC like population of cells from an aggressive cancer cell line, perform in vivo and in vitro phage display selections against the CSCs, and then characterize the resulting phage/peptides for further use as a diagnostic and therapeutic tool.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bacteriophage; Biomarkers; Cancer stem cells; Characterization/target validation; Peptide-based tumor -targeting; Screening

Mesh:

Substances:

Year:  2022        PMID: 35094358     DOI: 10.1007/978-1-0716-1811-0_41

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  32 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Prospective identification of tumorigenic prostate cancer stem cells.

Authors:  Anne T Collins; Paul A Berry; Catherine Hyde; Michael J Stower; Norman J Maitland
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

Authors:  Matilde Todaro; Miriam Gaggianesi; Veronica Catalano; Antonina Benfante; Flora Iovino; Mauro Biffoni; Tiziana Apuzzo; Isabella Sperduti; Silvia Volpe; Gianfranco Cocorullo; Gaspare Gulotta; Francesco Dieli; Ruggero De Maria; Giorgio Stassi
Journal:  Cell Stem Cell       Date:  2014-03-06       Impact factor: 24.633

Review 4.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

5.  The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse.

Authors:  Anna Merlos-Suárez; Francisco M Barriga; Peter Jung; Mar Iglesias; María Virtudes Céspedes; David Rossell; Marta Sevillano; Xavier Hernando-Momblona; Victoria da Silva-Diz; Purificación Muñoz; Hans Clevers; Elena Sancho; Ramón Mangues; Eduard Batlle
Journal:  Cell Stem Cell       Date:  2011-03-17       Impact factor: 24.633

6.  Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma.

Authors:  Phu Hung Nguyen; Julie Giraud; Lucie Chambonnier; Pierre Dubus; Linda Wittkop; Geneviève Belleannée; Denis Collet; Isabelle Soubeyran; Serge Evrard; Benoit Rousseau; Nathalie Senant-Dugot; Francis Mégraud; Frédéric Mazurier; Christine Varon
Journal:  Clin Cancer Res       Date:  2016-09-12       Impact factor: 12.531

7.  Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells.

Authors:  Lin Lv; Hai-Guang Liu; Si-Yang Dong; Fan Yang; Qing-Xuan Wang; Gui-Long Guo; Yi-Fei Pan; Xiao-Hua Zhang
Journal:  Tumour Biol       Date:  2016-01-09

8.  CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.

Authors:  Alexei V Salnikov; Jury Gladkich; Gerhard Moldenhauer; Manfred Volm; Jürgen Mattern; Ingrid Herr
Journal:  Int J Cancer       Date:  2010-02-15       Impact factor: 7.396

9.  Cancer stem cells in radiation resistance.

Authors:  Jeremy N Rich
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

10.  CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.

Authors:  E M Hurt; B T Kawasaki; G J Klarmann; S B Thomas; W L Farrar
Journal:  Br J Cancer       Date:  2008-02-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.